1. Home
  2. UEC vs NAMS Comparison

UEC vs NAMS Comparison

Compare UEC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Uranium Energy Corp.

UEC

Uranium Energy Corp.

HOLD

Current Price

$9.32

Market Cap

4.9B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$31.78

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEC
NAMS
Founded
2003
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.1B
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
UEC
NAMS
Price
$9.32
$31.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$18.95
$46.75
AVG Volume (30 Days)
8.3M
977.5K
Earning Date
06-01-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$66,837,000.00
N/A
Revenue This Year
N/A
$17.96
Revenue Next Year
$220.11
$540.65
P/E Ratio
N/A
N/A
Revenue Growth
29737.95
N/A
52 Week Low
$7.70
$21.14
52 Week High
$20.34
$42.21

Technical Indicators

Market Signals
Indicator
UEC
NAMS
Relative Strength Index (RSI) 34.96 42.75
Support Level N/A $29.23
Resistance Level $12.51 $31.72
Average True Range (ATR) 0.54 1.86
MACD -0.01 -0.38
Stochastic Oscillator 17.08 13.64

Price Performance

Historical Comparison
UEC
NAMS

About UEC Uranium Energy Corp.

Uranium Energy Corp is a uranium mining company engaged in the exploration, extraction, and processing of uranium and titanium concentrates across projects in the United States, Canada, and Paraguay. The Company operates through multiple segments, including uranium mining activities in Wyoming, Texas, Saskatchewan, and other regions, along with a corporate segment focused on investments and uranium inventory trading. It is expanding its portfolio of low-cost uranium projects in stable North American locations and operates a Wyoming-based ISR (In-Situ Recovery) Hub and Spoke platform. This platform is supported by two fully operational central processing plants and seven U.S. ISR uranium projects.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: